ALNY
Alnylam Pharmaceuticals Inc.
Price performance
Sep 18, 2026About
Company activity
28 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 07/30 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Strong Q2 2026 Financial Results and Revises Guidance | — | — | — |
| 05/27 | ALNY | 8-K | Alnylam Pharmaceuticals Expands Board and Announces Annual Meeting Results | — | — | — |
| 04/30 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Strong Q1 2026 Financial Results and Strategic Collaborations | — | — | — |
| 03/04 | ALNY | 8-K | Alnylam Pharmaceuticals Inc. Grants Special Equity Award to CEO Yvonne Greenstreet | — | — | — |
| 02/12 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Strong Q4 2025 Financial Results and Highlights Pipeline Progress | — | — | — |
| 01/12 | ALNY | 8-K | Alnylam Announces New Five-Year Strategy and Preliminary 2025 Financial Results | — | — | — |
| 12/11/25 | ALNY | 8-K | Alnylam Pharmaceuticals Announces Partial Repurchase of Convertible Senior Notes | — | — | — |
| 12/03/25 | ALNY | 8-K | Alnylam Appoints New Director and Announces Board Resignations | — | — | — |
| 10/30/25 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Strong Q3 2025 Financial Results and Raises Guidance | — | — | — |
| 10/03/25 | ALNY | 8-K | Alnylam Pharmaceuticals Enters into a $500M Credit Agreement | — | — | — |
| 09/12/25 | ALNY | 8-K | Alnylam Pharmaceuticals Completes Convertible Notes Offering | — | — | — |
| 09/10/25 | ALNY | 8-K | Alnylam Announces Convertible Senior Notes Offering | — | — | — |
| 07/31/25 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Strong Q2 2025 Financial Results and Raises Guidance | — | — | — |
| 06/18/25 | ALNY | 8-K | Alnylam Promotes Pushkal Garg to Chief Research and Development Officer | — | — | — |
| 05/13/25 | ALNY | 8-K | Alnylam Pharmaceuticals Approves Bylaw Amendment and Re-elects Directors | — | — | — |
| 05/01/25 | ALNY | 8-K | Alnylam Pharmaceuticals Announces Q1 2025 Financial Results and Key Approvals | — | — | — |
| 03/21/25 | ALNY | 8-K | Alnylam Pharmaceuticals Announces FDA Approval of AMVUTTRA for ATTR-CM | — | — | — |
| 03/05/25 | ALNY | 8-K | Dr. Phillip A. Sharp to Retire from Alnylam Board of Directors | — | — | — |
| 02/13/25 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Q4 2024 Financial Results | — | — | — |
| 01/13/25 | ALNY | 8-K | Alnylam Pharmaceuticals Announces Preliminary 2024 Financial Results and 2025 Guidance | — | — | — |
| 10/31/24 | ALNY | 8-K | Alnylam Pharmaceuticals Announces Quarterly Financial Results | — | — | — |
| 08/01/24 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Strong Q2 2024 Financial Results and Key Updates | — | — | — |
| 05/20/24 | ALNY | 8-K | Alnylam Pharmaceuticals Re-elects Board Members and Approves Executive Compensation | — | — | — |
| 05/02/24 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Strong Q1 2024 Financial Results | — | — | — |
| 03/04/24 | ALNY | 8-K | Alnylam Pharmaceuticals Announces Departure of Chief Legal Officer | — | — | — |
| 02/15/24 | ALNY | 8-K | Alnylam Pharmaceuticals Reports Strong 2023 Financial Performance and Sets 2024 Guidance | — | — | — |
| 01/19/24 | ALNY | 8-K | Alnylam Pharmaceuticals Announces Transition of Executive Vice President and CLO | — | — | — |
| 01/08/24 | ALNY | 8-K | Alnylam Pharmaceuticals Announces Preliminary 2023 Financial Results and Updates | — | — | — |
ALNY filing record
Alnylam Pharmaceuticals Inc. (ALNY): 28 8-K filings summarized, the most recent on Jul 30, 2026.
What the 8-K filings said
- Jul 30, 2026 · high impact
Alnylam Pharmaceuticals, Inc. reported a 74% increase in total net product revenues for Q2 2026, reaching $1.17 billion, driven by strong performance in its TTR franchise. The company revised its full-year 2026 TTR net product revenue guidance from $4.4-4.7 billion to $4.2-4.5 billion, reflecting normalized growth in…
Alnylam Pharmaceuticals Reports Strong Q2 2026 Financial Results and Revises Guidance - May 27, 2026 · high impact
Alnylam Pharmaceuticals, Inc. expanded its Board of Directors from ten to eleven members, electing Dr. Benjamin F. Cravatt as a Class III director. The Annual Meeting of Stockholders saw the re-election of three Class I directors, approval of executive compensation in a non-binding vote, and ratification of…
Alnylam Pharmaceuticals Expands Board and Announces Annual Meeting Results - Apr 30, 2026 · medium impact
Alnylam Pharmaceuticals, Inc. reported its first quarter 2026 financial results, achieving global net product revenues of $1,036 million, a 121% growth compared to Q1 2025. The company's TTR franchise, particularly AMVUTTRA, drove this growth with total TTR revenues of $910 million, a 153% increase year-over-year.…
Alnylam Pharmaceuticals Reports Strong Q1 2026 Financial Results and Strategic Collaborations - Mar 4, 2026 · high impact
Alnylam Pharmaceuticals, Inc. granted a special equity award to its Chief Executive Officer, Yvonne Greenstreet, M.D., M.B.A., under the Company's Second Amended and Restated 2018 Stock Incentive Plan. The award is fully performance-based and contingent upon the achievement of significant stock price appreciation by…
Alnylam Pharmaceuticals Inc. Grants Special Equity Award to CEO Yvonne Greenstreet - Feb 12, 2026 · high impact
Alnylam Pharmaceuticals, Inc. reported strong financial results for Q4 2025, with global net product revenues of $995 million, representing a 121% increase year-over-year. The company achieved profitability for the full year 2025, with GAAP net income of $314 million. Alnylam launched its 'Alnylam 2030' strategy…
Alnylam Pharmaceuticals Reports Strong Q4 2025 Financial Results and Highlights Pipeline Progress
SEC filings in the last five years
- 53 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K